Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer
- PMID: 21346227
- PMCID: PMC3057984
- DOI: 10.1093/jnci/djr030
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer
Abstract
Background: Triple-negative (ie, estrogen receptor [ER], progesterone receptor, and HER2 negative) breast cancer occurs disproportionately among African American women compared with white women and is associated with a worse prognosis than ER-positive (ER+) breast cancer. Hormonally mediated risk factors may be differentially related to risk of triple-negative and ER+ breast cancers.
Methods: Using data from 155,723 women enrolled in the Women's Health Initiative, we assessed associations between reproductive and menstrual history, breastfeeding, oral contraceptive use, and subtype-specific breast cancer risk. We used Cox regression to evaluate associations with triple-negative (N = 307) and ER+ (N = 2610) breast cancers and used partial likelihood methods to test for differences in subtype-specific hazard ratios (HRs).
Results: Reproductive history was differentially associated with risk of triple-negative and ER+ breast cancers. Nulliparity was associated with decreased risk of triple-negative breast cancer (HR = 0.61, 95% confidence interval [CI] = 0.37 to 0.97) but increased risk of ER+ breast cancer (HR = 1.35, 95% CI = 1.20 to 1.52). Age-adjusted absolute rates of triple-negative breast cancer were 2.71 and 1.54 per 10,000 person-years in parous and nulliparous women, respectively; by comparison, rates of ER+ breast cancer were 21.10 and 28.16 per 10,000 person-years in the same two groups. Among parous women, the number of births was positively associated with risk of triple-negative disease (HR for three births or more vs one birth = 1.46, 95% CI = 0.82 to 2.63) and inversely associated with risk of ER+ disease (HR = 0.88, 95% CI = 0.74 to 1.04). Ages at menarche and menopause were modestly associated with risk of ER+ but not triple-negative breast cancer; breastfeeding and oral contraceptive use were not associated with either subtype.
Conclusion: The association between parity and breast cancer risk differs appreciably for ER+ and triple-negative breast cancers. These findings require further confirmation because the biological mechanisms underlying these differences are uncertain.
Comment in
-
Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?J Natl Cancer Inst. 2011 Mar 16;103(6):451-3. doi: 10.1093/jnci/djr046. Epub 2011 Feb 23. J Natl Cancer Inst. 2011. PMID: 21346225 No abstract available.
Similar articles
-
Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.Clin Breast Cancer. 2014 Dec;14(6):426-34. doi: 10.1016/j.clbc.2014.05.003. Epub 2014 Jun 23. Clin Breast Cancer. 2014. PMID: 25034438
-
Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.Clin Breast Cancer. 2014 Dec;14(6):417-25. doi: 10.1016/j.clbc.2014.04.003. Epub 2014 Jun 2. Clin Breast Cancer. 2014. PMID: 24970715 Free PMC article.
-
Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.Breast Cancer Res. 2024 May 31;26(1):88. doi: 10.1186/s13058-024-01834-5. Breast Cancer Res. 2024. PMID: 38822357 Free PMC article.
-
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.Cancer Treat Rev. 2016 Sep;49:65-76. doi: 10.1016/j.ctrv.2016.07.006. Epub 2016 Jul 29. Cancer Treat Rev. 2016. PMID: 27529149 Review.
-
Reproductive risk factors and breast cancer subtypes: a review of the literature.Breast Cancer Res Treat. 2014 Feb;144(1):1-10. doi: 10.1007/s10549-014-2852-7. Epub 2014 Jan 30. Breast Cancer Res Treat. 2014. PMID: 24477977 Free PMC article. Review.
Cited by
-
Role of obesity in the risk of breast cancer: lessons from anthropometry.J Oncol. 2013;2013:906495. doi: 10.1155/2013/906495. Epub 2013 Feb 3. J Oncol. 2013. PMID: 23431300 Free PMC article.
-
A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium.Breast Cancer Res. 2015 Feb 21;17(1):22. doi: 10.1186/s13058-015-0535-x. Breast Cancer Res. 2015. PMID: 25849024 Free PMC article.
-
Molecular pathways involved in pregnancy-induced prevention against breast cancer.Front Endocrinol (Lausanne). 2014 Dec 10;5:213. doi: 10.3389/fendo.2014.00213. eCollection 2014. Front Endocrinol (Lausanne). 2014. PMID: 25540638 Free PMC article. Review.
-
Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts.Breast Cancer Res. 2018 Dec 3;20(1):147. doi: 10.1186/s13058-018-1073-0. Breast Cancer Res. 2018. PMID: 30509329 Free PMC article.
-
A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.Cancer Causes Control. 2014 Mar;25(3):309-19. doi: 10.1007/s10552-013-0332-8. Epub 2013 Dec 17. Cancer Causes Control. 2014. PMID: 24343304 Free PMC article.
References
-
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
-
- Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–5374. - PubMed
-
- Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502. - PubMed
-
- Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217–1226. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01WH22110/WH/WHI NIH HHS/United States
- N01WH42129-32/WH/WHI NIH HHS/United States
- N01WH32119/WH/WHI NIH HHS/United States
- T32 CA09168/CA/NCI NIH HHS/United States
- N01WH32100-2/WH/WHI NIH HHS/United States
- N01WH32108-9/WH/WHI NIH HHS/United States
- N01WH42107-26/WH/WHI NIH HHS/United States
- N01WH32118/WH/WHI NIH HHS/United States
- N01WH32122/WH/WHI NIH HHS/United States
- R25-CA94880/CA/NCI NIH HHS/United States
- N01WH32105-6/WH/WHI NIH HHS/United States
- N01WH32111-13/WH/WHI NIH HHS/United States
- N01WH32115/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous